Let's talk medical research

We’re thrilled to share that today, we announced an important collaboration with Beyond Celiac, the leading celiac disease organization working to drive diagnosis, advance research, and accelerate the discovery of new treatments and a cure. We’ve been working with this incredible organization to make our celiac disease clinical trial search even better for patients and caregivers — and we’re now ...

We often reference our patient database: 400,000+ patients who have raised their hands to take part in medical research and shared health data to help us determine eligibility. The beauty of the Antidote database is that it provides a real-word picture of true patient populations — their demographic information as well as health details such as conditions they have, medications they’re on, and ...

Happy Clinical Trials Day! Here at Antidote, today is an opportunity to talk about why medical research matters – and to celebrate the volunteers who make it possible.

For people living with hemophilia, a chronic condition in which blood doesn’t clot normally, treatment options are limited and the threat of internal bleeding can be very serious. That’s why research that’s currently underway to identify new and better ways to manage the condition is so important, and why we were excited to support a recent project to push hemophilia research forward.

Diversity, equity, and inclusion (DEI) is a hot topic in clinical research — and for good reason. If medications aren’t tested on populations that reflect the real world, how will we know what works best for all patients? In order to understand the importance of this issue, and recognize progress when it comes, we’ve put together a one-pager that provides a snapshot of the current state of ...

Knee osteoarthritis is the most common form of arthritis worldwide, and its prevalence is expected to continue to rise for years to come. For those that live with this condition, it causes pain, tiredness, loss of flexibility, a grating sensation, bone spurs, and swelling — all constant reminders of the need for new and better treatment options to replace the cartilage that has worn down over ...

When the pandemic began, more than 1,000 trials were delayed as the focus shifted to minimizing coronavirus exposure and driving COVID-19 vaccine and treatment trials. The reasons were varied — patients weren’t allowed into studies, study starts were delayed, and recruitment was slow. One thing is clear: the impact of these delays on the progress of medical research will likely be felt for years ...

As the COVID-19 pandemic surged in late 2020, the urgency of research was felt by all. At Antidote, our mission has always been to enable faster medical innovation by transforming how patients and researchers connect, and we were eager to contribute to the global effort to drive COVID-19 research forward. Our latest patient recruitment case study shares how Antidote contributed to ensuring three ...

We’re thrilled to share that Antidote’s Executive Vice President of Business Development, Dave Mauro, has been named to this year’s PharmaVOICE 100. For sixteen years, the PharmaVOICE 100 has recognized the 100 most inspiring, motivational, and transformational individuals in the life sciences industry as identified by the global community.

Postoperative Corneal Induced Chronic Pain (also known as CICP) is a condition that causes chronic pain and blurred vision after eye surgery. For the 300,000 people who experience this, effective treatments could drastically improve their quality of life.